colorectal cancer
Conditions
Interventions
Experimental group:Give fruquintinib combined with TAS-102
Sponsors
Sichuan Cancer Hospital
Eligibility
Sex/Gender
Male
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 75 years, male or female; 2.After colonoscopy and histopathological biopsy, the diagnosis was confirmed as primary colon cancer or primary rectal cancer; 3.The tumor was metastatic and advanced after second-line treatment (including fluorouracil, oxaliplatin and irinotecan); 4.More than 1 month after the last chemotherapy; 5.Karnofsky score >= 80, or ECoG physical condition score >= 1, and estimated survival time >= 3 months; 6.Those who did not participate in other clinical studies; 7.Hypertension was well controlled; 8.Adequate blood function: absolute neutrophil count (ANC) >= 2 x 10^9/L and platelet count >= 100 x 10^9/L and hemoglobin >= 9 g/dl; 9.Sufficient liver function: total bilirubin = 60 ml / min; 11.ECG was normal and there was no unhealed wound in the body; 12.All tumors had at least one measurable lesion; 13.They signed informed consent and volunteered to participate in this study.
Exclusion criteria
Exclusion criteria: 1.Patients with bone marrow suppression, prone to infection and bleeding risk; 2.They were complicated with severe cardiovascular and cerebrovascular diseases; 3.Patients with warfarin, heparin and other drugs, or with hematopoiesis abnormality; 4.They were not conscious and could not express their subjective symptoms and mental illness.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Total survival time;Safety of the experimental group;Quality of life; | — |
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactYin Xude
Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China
Outcome results
None listed